Highly interesting events on transglutaminase, celiac disease, thromoprophylaxis or other related topics.
Please contact us in advance to make an appointment to meet at the venue.



Life Sciences 2019: Post-translational modifications and cell signalling
17. March 2019 - 18. March 2019
Location Nottingham, UK
External Link eventsforce.net
Comment Session on "Transglutaminase mediated post-translational modifications in human disease"
 
 
10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)
16. May 2019 - 17. May 2019
Location Sheffield, UK
External Link SRCA
Comment Learn more about the latest findings in cerebellar research.
 
 
18th International Celiac Disease Symposium ICDS
04. September 2019 - 07. September 2019
Location Paris, France
External Link ICDS
Comment The 18th ICDS will bring together the leaders in celiac disease research.
 
 

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

    All events
  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

    All events
  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

    All events